SELLAS Life Sciences Group, Inc.
No SEC Form 4 filings for $SLS in the last 30 days.
See all $SLS insider activity →Simply Wall St reports SELLAS Life Sciences Group (SLS) drew renewed attention after its Q2 2026 results, showing a net loss of $9.61 million and updated loss per share from continuing operations. The stock closed at $11.05 and trades at a 20.2x price-to-book versus a 4.9x peer average and 2.4x industry average, despite reporting a $29.457 million loss and under $1 million revenue.
SELLAS Life Sciences Group, Inc. (SLS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 sls-202608118xkexhibit991.htm EX-99.1 Document Exhibit 99.1 SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update – Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Followi
Sellas Life Sciences Group (SLS) shares rose more than 4% to $8.12, heading toward a fifth straight weekly gain. CEO Angelos Stergiou cited real-world MD Anderson data in elderly AML patients treated with intensive regimens, and said the results support the Phase 3 REGAL trial of GPS. REGAL had reached 78 events as of May 11, with two remaining before final analysis.
Over the past 7 days, alphai's AI scored 5 news stories mentioning SLS (SELLAS Life Sciences Group, Inc.). Coverage has skewed bullish: 3 bullish, 1 neutral, and 1 bearish.
Recent SLS coverage spans financial news, technology and market movers.
The article frames the stock as momentum-driven but valuation-stretched, using the reported loss and a high P/B multiple to highlight downside risk.
Near-term catalysts are tied to REGAL trial event timing (database lock and topline after the 80th event) and SLS009 Phase 2 topline timing in Q4 2026, alongside higher operating costs and cash runway signals.
New real-world remission and transplant-rate details reinforce the GPS REGAL narrative ahead of final analysis, supporting near-term momentum.
Clinical trial progress toward a pivotal readout is a binary-style catalyst that can materially change probability-weighted outcomes and valuation.
The filing is a new disclosure of a sizable passive stake, which can affect perceived ownership overhang and potential future activism, but it does not indicate control changes.
alphai scores every news story that mentions SLS with an AI model for sentiment and relevance, and aggregates insider trades from SELLAS Life Sciences Group, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Simply Wall St reports SELLAS Life Sciences Group (SLS) drew renewed attention after its Q2 2026 results, showing a net loss of $9.61 million and updated loss per share from continuing operations. The stock closed at $11.05 and trades at a 20.2x price-to-book versus a 4.9x peer average and 2.4x industry average, despite reporting a $29.457 million loss and under $1 million revenue.
5 min readSELLAS Life Sciences Group, Inc. (SLS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 sls-202608118xkexhibit991.htm EX-99.1 Document Exhibit 99.1 SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update – Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Followi
4 min readSellas Life Sciences Group (SLS) shares rose more than 4% to $8.12, heading toward a fifth straight weekly gain. CEO Angelos Stergiou cited real-world MD Anderson data in elderly AML patients treated with intensive regimens, and said the results support the Phase 3 REGAL trial of GPS. REGAL had reached 78 events as of May 11, with two remaining before final analysis.
4 min readNebius Group (NBIS), Cisco Systems (CSCO), and Sellas Life Sciences Group (SLS) hit 52-week highs. Nebius reported Q1 revenue of $399M, up 684% YoY, and raised 2026 ARR guidance to $7B-$9B, plus access to up to 1.2 GW power for an AI facility. Cisco raised AI infrastructure order forecast to about $9B and reported Q3 revenue of $15.8B. SLS said its Phase 3 REGAL AML study is nearing a final event threshold and reported $107M+ cash.
4 min readState Street Corporation and related investment adviser subsidiaries filed a Schedule 13G for SELLAS Life Sciences Group Inc. As of 06/30/2026, they reported passive beneficial ownership of 12,996,558 common shares, about 7% of the outstanding class. The filing shows shared voting power over 12,677,559 shares and shared dispositive power over 12,996,558 shares.
2 min readSellas Life Sciences Group (SLS) shares rose about 2% to above $5 after CEO Angelos Stergiou said the company was invited to the EU Parliament’s Public Health Committee to discuss the EU Biotech Act and drug-approval policy. Investors also focus on its Phase 3 REGAL AML trial nearing an 80-event overall-survival threshold, plus a proposed 20M-share equity plan expansion.
6 min readSellas Life Sciences Group (SLS) shares rose in premarket trading after CEO Angelos Stergiou said GPS in its AML Phase 3 Regal trial has a “very good chance” to match or beat earlier survival results. Regal reached 78 events as of May 11, with two events left before final analysis. Company targets median overall survival of 12.6 months vs 8.1 months.
4 min readSellas Life Sciences Group (SLS) shares rose 18% to a 4-year high as its Phase 3 Regal trial of galinpepimut-S (GPS) in AML nears the final analysis stage. CEO Angelos Stergiou said survival appears longer than expected; the study had 78 events as of May 11, with two remaining. Success target: median OS 12.6 months vs 8.1 months.
5 min readU.S. stock futures rose early Tuesday after Monday’s earnings-led rally. Nasdaq futures were up 0.7% and S&P 500 futures up 0.1% at 4:00 a.m. ET. Investors focused on Palantir and Snap results, with AMD, Lucid and SpaceX set for after-hours earnings. Retail sentiment stayed bearish for SPY and QQQ.
6 min readU.S. stock index futures rose overnight after strong earnings. Nasdaq-100 futures were up 0.11%, Dow futures up 0.22%, and S&P 500 futures up 0.13%. Palantir (PLTR) reported a 93% revenue jump and shares rose about 14%. GameStop (GME) fell after converting about $1.4B notes into Class A shares. Iran said it is talking with Oman on a temporary Strait of Hormuz shipping arrangement.
6 min read
